Market Tracker

09/29 5:20pm ET
Customize

Novartis AG (NYSE:NVS)

101.88
Delayed Data
As of Sep 29
 -0.45 / -0.44%
Today’s Change
74.24
Today|||52-Week Range
105.61
+12.30%
Year-to-Date
Novartis (NVS) Dips More Than Broader Markets: What You Should Know
Sep 29 / Zacks.com - Paid Partner Content
Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer Studies
Sep 25 / Zacks.com - Paid Partner Content
Market Today: Nike's Earnings Beat, Tesla Faces EEOC Lawsuit, and Novartis Executive Joins Teva
Sep 28 / GuruFocus News - Paid Partner Content
FDA Expands Lilly (LLY) Jardiance Label in Chronic Kidney Disease
Sep 25 / Zacks.com - Paid Partner Content
Ionis (IONS) Inks New Deal With Roche to Develop Novel RNA Drugs
Sep 28 / Zacks.com - Paid Partner Content
Novartis (NVS) Dips More Than Broader Markets: What You Should Know
Sep 22 / Zacks.com - Paid Partner Content
Pliant (PLRX) Up on Success of Mid-Stage Liver Disease Study
Sep 27 / Zacks.com - Paid Partner Content
Travere (TVTX) Slumps 41% on Mixed Results From IgAN Drug Study
Sep 22 / Zacks.com - Paid Partner Content
Intercept Pharmaceuticals (ICPT) Surges on Acquisition Deal
Sep 27 / Zacks.com - Paid Partner Content
Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze
Sep 22 / Zacks.com - Paid Partner Content
Ionis (IONS) Meets Rare Disease Drug Study Goal, Stock Up 8.5%
Sep 27 / Zacks.com - Paid Partner Content
Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag
Sep 21 / Zacks.com - Paid Partner Content
Novartis' (NVS) Sandoz Gets EC Nod for Tysabri's Biosimilar
Sep 26 / Zacks.com - Paid Partner Content
FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma
Sep 20 / Zacks.com - Paid Partner Content
Novartis (NVS) Lutathera Meets Primary Goal in Phase III Study
Sep 25 / Zacks.com - Paid Partner Content
Novartis' (NVS) Shareholders Approve Sandoz Separation
Sep 18 / Zacks.com - Paid Partner Content